Assessment of Serum Uric Acid Levels in Multiple Sclerosis during Disease-Modifying Treatment

  title={Assessment of Serum Uric Acid Levels in Multiple Sclerosis during Disease-Modifying Treatment},
  author={Aleksandra Podlecka-Piętowska and Joanna Przybek and Kamil Chorążka and Monika Nojszewska and Beata Zakrzewska-Pniewska and Anna Kaminska},
  journal={Journal of multiple sclerosis},
Objective: Uric acid is a potent endogenous antioxidant and scavenger of peroxynitrite (PN), which hypothesized to be involved in the pathogenesis of multiple sclerosis (MS). Some studies reported lower levels of UA in MS patients compared with controls, whereas other studies found no difference. The main purpose of this analysis was to verify the hypothesis on lower serum levels of UA in MS patients compared with controls.Materials and methods: We examined 80 patients with clinically defined… 
2 Citations

Tables from this paper

Electrochemical Characterization of Iron (III) Doped Zeolite-Graphite Composite Modified Glassy Carbon Electrode and Its Application for AdsASSWV Determination of Uric Acid in Human Urine
  • Meareg Amare
  • Materials Science, Chemistry
    International journal of analytical chemistry
  • 2019
Under optimized method and solution parameters, linear dependence of peak current on uric acid concentration in a wide range of 1-120 μM, low detection limit value, replicate results with low RSD, and excellent recovery results validated the developed adsorptive anodic stripping square wave voltammetric (AdsASSWV) method for determination of uric Acid even in aqueous human urine samples.
Assessment of Serum Uric Acid Levels in Multiple Sclerosis during Disease-Modifying Treatment
Data suggest that UA concentration is lower in MS patients than in control group, and it seems that low uric acid levels indicate patients with a higher risk of disease progression.


Serum uric acid and multiple sclerosis
The view that reduced UA in MS is a primary, constitutive loss of protection against oxidative agents, which deserves further pathogenetic elucidation aimed at future therapeutic strategies is favors the view.
Uric acid levels in sera from patients with multiple sclerosis
It is suggested that serum UA might serve as a possible marker of disease activity in MS and provide support to the potential beneficial therapeutic effect of radical-scavenging substances in MS.
Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis
The results support the significance of UA in the pathogenesis of multiple sclerosis and suggest CSF UA concentrations may not be a reliable marker of disease activity in MS since its concentration is dependent on leakage of UA molecules from serum through the damaged BBB and the balance between consumption/production within the central nervous system (CNS).
Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis
Investigating serum UA changes during open-label treatment of relapsing MS with GAA found increasing UA, a natural inhibitor of free radicals, may represent a mechanism of action of glatiramer acetate in MS.
Serum uric acid levels in multiple sclerosis patients inversely correlate with disability
This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score, which is associated with clinical relapse in multiple sclerosis patients.
Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis
The results of the present study suggest that elevated concentrations of uric acid, indeed within the physiological range, are likely linked to the presence of BMS.
Serum uric acid levels of patients with multiple sclerosis and other neurological diseases.
Serum UA levels were independently correlated with gender and duration of MS, but neither with MRI activity, disability nor subtypes of the disease in MS patients, suggesting that UA has two biphasic functions: neuroprotective and injurious.
Serum uric acid and risk of multiple sclerosis
The results of this study suggest that serum urate is not a strong predictor of MS risk, consistent with the interpretation that the lower urate levels among multiple sclerosis cases are a consequence rather than a cause of the disease.
Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease
Serum UA levels are raised and maintained at elevated levels for a year and more without reported side-effects by oral administration of its precursor inosine, providing evidence that serum UA levels can be readily manipulated.
Nonenzymatic antioxidants of blood in multiple sclerosis
Investigation of the plasma level of lipid peroxides expressed in terms of malone dialdehyde and changes in blood nonenzymatic antioxidants in multiple sclerosis patients with exacerbation or in remission suggests increased free radical production and consumption of the scavenger molecules during the active phase of the disease.